MNOV · Medicinova Inc
$1.48
-0.09 (-5.73%)
At close · Aug 26
Market Cap
$73.34M
Shares
49.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.48
Open$1.57
Day$1.43–1.58
52W close$1.18–1.88
Avg vol 30d41K
Short int331K · 0.7% float · 11.8d
Short vol74%
DataJan 2020–Aug 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
+9%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
+14%
trailing
YTD return
+13%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.67% of float · ▼ -4.3% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
29 holders — mid 3-yr range
Squeeze score
52
elevated · 0–100
Fundamentals
EPS growth
−4%
Y/Y
Free cash flow
$-9.8M
Balance sheet
$16.4M
net cash
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Feb 20, 2026
Operating expenses
· fiscal year ending December 31, 2026
$16.2M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.67% of float · ▼ -4.3% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
29 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 43%
Range high $2
vs 200-day avg +4%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNOV
this stock
Medicinova Inc
|
$73.34M | +13.0% | — | — | 0.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNOV | +7.3% | +14.7% | +13.9% | +11.3% | +13.0% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +7.6% | +9.7% | +1.4% | +8.7% | +0.6% |
Key facts
CIK
1226616
CUSIP
58468P206
13F (30d)
28 filings
28 filers
Visit website
Investor relations